The reiteration of an Outperform rating and a maintained price target of $32 by a reputable analyst like Gregory Renza from RBC Capital is likely to instill confidence among investors and could lead to a positive short term impact on Verastem's stock price. This endorsement reaffirms the analyst's positive outlook on the company's future performance.